Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Galectin Therapeutics Inc shares valued at $950,105 were sold by Shlevin Harold H. on Dec 08 ’25. At $5.98 per share, Shlevin Harold H. sold 159,000 shares. The insider’s holdings dropped to 11,206 shares worth approximately $61520.94 following the completion of this transaction.
Also, Shlevin Harold H. sold 16,790 shares, netting a total of over 105,206 in proceeds. Following the sale of shares at $6.27 each, the insider now holds 11,206 shares.
Before that, HAROLD SHLEVIN had added 16,790 shares to its account. In a trade valued at $104,198, the DIRECTOR bought Galectin Therapeutics Inc shares for $6.21 each.
Analysts at H.C. Wainwright resumed the stock at ‘”a Buy”‘ outlook in a report released in mid August. As of February 13, 2019, B. Riley FBR has initiated its “Buy” rating for GALT. Earlier on December 07, 2017, H.C. Wainwright resumed its rating. Their recommendation was “a Buy” for GALT stock.
Analyzing GALT Stock Performance
On last trading session, Galectin Therapeutics Inc [NASDAQ: GALT] plunged -7.58% to $5.49. The stock’s lowest price that day was $5.11, but it reached a high of $6.128 in the same session. During the last five days, there has been a drop of approximately -3.68%. Over the course of the year, Galectin Therapeutics Inc shares have jumped approximately 168.46%. Shares of the company reached a 52-week high of $6.66 on 12/05/25 and a 52-week low of $1.07 on 01/14/25.
Support And Resistance Levels for Galectin Therapeutics Inc (GALT)
According to the 24-hour chart, there is a support level at 5.02, which, if violated, would cause prices to drop to 4.54. In the upper region, resistance lies at 6.05. The next price resistance is at 6.60. RSI (Relative Strength Index) is 47.98 on the 14-day chart, showing neutral technical sentiment.
Is Galectin Therapeutics Inc subject to short interest?
Stocks of Galectin Therapeutics Inc saw a sharp steep in short interest on 2025-11-28 dropping by 86983.0 shares to 6.82 million. Data from Yahoo Finance shows that the short interest on 2025-10-31 was 6.9 million shares. A decline of -1.28% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 16.46 of the overall float, the days-to-cover ratio (short ratio) decline to 16.46.
Which companies own the most shares of Galectin Therapeutics Inc (GALT)?
On November 28, 2017, H.C. Wainwright assigned a price target of “a Buy” to the stock and reiterated coverage with a $6.
